CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (443)	12/6/1999 10:57:00 PM
From: Vector1	of 666

By Stephanie O'Brien, CBS MarketWatch Last Update: 5:41 PM ET Dec 6, 1999 Movers & Shakers SAN FRANCISCO (CBS.MW) -- Shares of Coulter Pharmaceutical rose 11.1 percent Monday after the company said its drug Bexxar appears to be effective in treating different types of types of non-Hodgkin's lymphoma when combined with other drugs. Today on CBS MarketWatch Nasdaq ends day on record ground AT&T announces wireless tracking stock AT&T aligns with open-access advocates Coca-Cola boss to step down Cyber shares extend gains More top stories... CBS MarketWatch Columns Updated: 12/6/99 4:00:40 PM ET Coulter (CLTR: news, msgs) shares rose 1 7/8 to 18 3/4. Results of the studies, which were in collaboration with SmithKline Beecham (SBH: news, msgs) were reported at the American Society of Hematology Annual Meeting in New Orleans. The data showed high response rates and long periods of cancer remission with Bexxar to treat non-Hodgkin's lymphoma. "Initial evidence that a therapy is working comes in the form of responses, particularly complete responses," Dr. Julie Vose, vice chair and professor at the University of Nebraska Medical Center. "The response and duration data for Bexxar are compelling and continue to support the promise of this radioimmunotherapy for the treatment of low-grade and transformed low-grade NHL," Vose said. Earlier this year, Bexxar faced a setback after the U.S. Food and Drug Administration asked Coulter to modify its marketing application for the drug. See full story. Pharmaceutical giant SmithKline Beecham, whose shares fell 3 1/16 to 66 13/16 during Monday's trading, is a marketing partner for Bexxar.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next